The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | R-CHOP versus R-bendamustine in FL
Stefano Luminari, MD, University of Modena and Reggio Emilia, Modena, Italy, describes the effect of immuno-chemotherapy in the Phase III FOLL12 trial (EudraCT: 2012-003170-60), which assessed patients receiving R-CHOP or rituximab with bendamustine, followed by rituximab maintenance or a response adapted post induction management in patients with follicular lymphoma. Administration of R-CHOP or rituximab with bendamustine was left to the doctor’s discretion and both regimes were found to yield similar responses and progression-free survival in patients. Maintenance rituximab was additionally found to be superior to the response-based post-induction approach. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
